Internal link ProQR Strengthens Leadership with Appointments of CFO and CMO to Support Next Phase of Growth April 14, 2025 at 11:00 AM UTC
Internal link ProQR Announces Year End 2024 Operating and Financial Results März 13, 2025 at 11:00 AM UTC
Internal link ProQR Announces Webcast of Presentation at Upcoming HC Wainwright BIOCONNECT Conference Dezember 18, 2020 at 12:00 PM UTC
Internal link ProQR to Present at 3rd Annual Evercore ISI Virtual HealthCONx Conference November 18, 2020 at 12:00 PM UTC
Internal link ProQR Announces Third Quarter 2020 Operating and Financial Results November 16, 2020 at 12:00 PM UTC
Internal link ProQR Announces Virtual Presentations at American Academy of Ophthalmology (AAO) November 02, 2020 at 12:00 PM UTC
Internal link ProQR Appoints Naveed Shams, MD, PhD as Chief Scientific Officer Oktober 05, 2020 at 11:00 AM UTC
Internal link ProQR Announces Virtual Presentations at Scientific Conferences September 24, 2020 at 08:10 PM UTC
Internal link ProQR to Participate in Upcoming Investor Conferences September 03, 2020 at 11:00 AM UTC
Internal link ProQR Announces Second Quarter 2020 Operating and Financial Results August 06, 2020 at 08:30 PM UTC
Internal link ProQR Strengthens Scientific Advisory Board with Leaders in Inherited Retinal Disease and RNA Therapy Juli 21, 2020 at 11:00 AM UTC
Internal link ProQR Announces $30 Million Strategic Convertible Debt Financing Agreement with Pontifax Ventures Juli 14, 2020 at 08:30 PM UTC
Internal link ProQR Announces Expert Perspectives Call on LCA10 and Sepofarsen Juli 13, 2020 at 08:30 PM UTC
Internal link ProQR Announces Expert Perspectives Conference Call Series Juni 12, 2020 at 11:00 AM UTC
Internal link ProQR Announces Virtual Presentation of Phase 1/2 Sepofarsen Data Through the Association for Research in Vision and Ophthalmology (ARVO) Juni 08, 2020 at 11:00 AM UTC
Internal link ProQR Announces First Quarter 2020 Operating and Financial Results Mai 07, 2020 at 11:00 AM UTC
Internal link ProQR Announces Positive Findings From an Interim Analysis in the Phase 1/2 trial of QR-421a for Usher Syndrome and Provides Business Update März 31, 2020 at 10:00 AM UTC
Internal link ProQR to Present Findings from Phase 1/2 Interim Analysis of QR-421a for Usher Syndrome März 25, 2020 at 08:15 PM UTC
Internal link ProQR Announces Fourth Quarter and Full Year 2019 Results and Provides Business Update Februar 26, 2020 at 12:00 PM UTC
Internal link ProQR to Present at Cowen and Company 40th Annual Health Care Conference Februar 24, 2020 at 12:00 PM UTC
Internal link ProQR Therapeutics Teams Up with the Foundation Fighting Blindness and Blueprint Genetics to Support the My Retina Tracker® Program for People Living with Inherited Retinal Diseases Februar 06, 2020 at 12:00 PM UTC
Internal link ProQR Receives Rare Pediatric Disease Designation from FDA for QR-421a Januar 30, 2020 at 12:00 PM UTC
Internal link ProQR Announces Extraordinary General Meeting of Shareholders Dezember 27, 2017 at 12:00 PM UTC
Internal link ProQR Receives Orphan Drug Designation from EMA for Drug Candidate QR-313 for Dystrophic Epidermolysis Bullosa November 29, 2017 at 12:00 PM UTC